2003, Immune Response, Therapies and Vaccine

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2003

Immune Response

Therapies

Vaccine

Enlisting Monoclonal Antibodies in the Fight Against COVID-19

NIH Director's Blog: Drug Development

MAY 21, 2020

Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19. In the U.S.

Virus

Virus Vaccine Laboratories Small Molecule

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

OCTOBER 4, 2023

10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour.

Small Molecule

Small Molecule Drugs Immune Response Targeted Protein Degradation

Drug Discovery Digest

Enlisting Monoclonal Antibodies in the Fight Against COVID-19

Antibody-drug conjugates payloads: then, now and next

Stay Connected